Abstract | INTRODUCTION: AREAS COVERED: A number of epidemiological and preclinical studies have proven the potential benefit and critical role of omega-3 PUFA in the development and management of major depressive disorder (MDD). In addition, recently independent clinical trials and meta-analyses have also provided superidority of omega-3 PUFA over placebo as monotherapy or augmentation agent in the treatment of MDD. This article presents a brief overview of the evidence to date about the clinical application and biological mechanisms of omega-3 PUFA in the treatment of MDD. EXPERT OPINION: Given the potential action mechanism, clinical benefits and currently available clinical trial data, omega-3 PUFAs may deserve greater attention and wider application for treatment of MDD. However, the practical utility of omega-3 PUFA as one of promising alternative agent for treatment of MDD still have many questions unresolved to be fully addressed in near future.
|
Authors | Kuan-Pin Su, Sheng-Min Wang, Chi-Un Pae |
Journal | Expert opinion on investigational drugs
(Expert Opin Investig Drugs)
Vol. 22
Issue 12
Pg. 1519-34
(Dec 2013)
ISSN: 1744-7658 [Electronic] England |
PMID | 24083675
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Antidepressive Agents
- Fatty Acids, Omega-3
|
Topics |
- Animals
- Antidepressive Agents
(pharmacology, therapeutic use)
- Depressive Disorder, Major
(drug therapy)
- Fatty Acids, Omega-3
(pharmacology, therapeutic use)
- Humans
|